Replies to post #733634 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

flipper44,

I believe you are definitely on to something. A specific lipid trigger could quite possibly disrupt lipid balance in cancer cells and that will almost instantly cause cancer cell death. Finding the right interface to disrupt lipid balance was thought to be a potential Holy Grail type of finding in research I read through about 5-6 years ago. DCs programmed to do this is the safest way to approach this as this creates a specific set of on site instructions that would only target cancer cells through likely proper activation of T and B cells. Best wishes.

[dennisdave]

thank you Flipper very encouraging.

No wonder LP was talking about massive hiring to come. We must have a BP alignment to announce very soon. IMO.

where or when was LP talking about massive hiring to come?

[StockFollower]

Flipper44 - Sticky this post!

Brilliant!!!

SF

[Mortimerduke]

Flipper44, your investigative analytic skill is more than impressive. Thank you for sharing the knowledge you've accumulated on this complicated subject! Enjoy the rest of your weekend.

[georgebailey]

What I’ve been focused on is how nwbo is leveraging diagnostic tools to run “experiments” that are designed to pinpoint combinations that are highly likely to succeed in trials and commercialize.We are talking about saving years and billions in failed attempts and therefore created a very real new paradigm in managing cancer affordably. Hence, the dendretic franchise model. This is half of the total solution I.e. developing product(s) to manage cancer.
The other half is production and delivery….Edens and local clinics.
All the above is happening now.

[ATLnsider]

Thanks flipper44. I also agree that the new formulation of DCVax-L and DCVax-Direct will include an inflammation-activating lipid.

But, in my opinion, and as outlined in the patent application you linked, the inflammation-activating lipid will be used in addition to the maturation and immune-boosting agent.

All of these together, will hyperactivate the dendritic cells in both DCVax-L and DCVax-Direct.

[CrashOverride]

Thanks for the excellent insight!

[Chiugray]

What’s truly amazing is that tumor eradication is not the best thing about hyperactivated dendritic cells. What’s really amazing is the durable immune memory they create.

Flipper, Great post.
Tumor eradication = Efficacy
Durable immune memory = Cure

Sometimes it still amazes me that even though we are waiting on approval for DCVax-L, based on its spectacular results for the most difficult cancer GBM, it is still just the 1st generation of the larger DCVax technology platform.

Already we are seeing the many DCVax next-gen level and type of improvements on the horizon: Direct, adjuvant for modulating the tumor microenvironment, and immune-boosting / hyperactivating the dendritic cells. It seems to me we are just beginning to touch on the vast potential of DCs. After all they are the "General" of the immune system, the information gatherers to inform the type and size of the body's response. And DCVax will continually adapt by leveraging our immune system that is already forever adapting to new diseases as they come up.

[flipper44]

I was just following up on the hyperactive dendritic cell patent application, and noticed, much to my surprise, that the U.S. application, while filed in 2020, was not published until April 18, 2024. (in other countries, it was published much sooner)

I could be mistaken, because the u.s. patent office is getting harder, not easier for the public to search, but it appears both Dr. Bosch and Dr. Kagan were moving forward together on the published version.

If so, this would confirm my recent intuition we cooperated, “inlicensed” and/or merged this tech with/from Dr. Kagan/Children’s Mercy Hospital. I think there is a Harvard connection somewhere in there as well, if memory serves the news articles.

A lot of the documents don’t appear on my interface, I probably need to use a different device, but again, unlike our applications on hyperactive DCs in other countries, we waited four years to allow publication in the U.S. after the initial application. There must be a reason for this.

(By August 12, 2024 it was listed as DOCKETED NEW CASE - READY FOR EXAMINATION)